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ARTICLE
Widespread B cell perturbations in HIV-1 infection
afflict naive and marginal zone B cells
Thomas Liechti1, Claus Kadelka1,2, Dominique L. Braun1,2, Herbert Kuster1,2, Jürg Bo¨ni1, Melissa Robbiani3, Huldrych F. Günthard1,2,
and Alexandra Trkola1
Perturbations in B cells are a hallmark of HIV-1 infection. This is signified by increased numbers of exhausted CD21neg memory
B cells, driven by continuous antigen-specific and bystander activation. Using high-dimensional flow cytometry, we
demonstrate that this exhausted phenotype is also prevalent among peripheral antigen-inexperienced naive and marginal
zone (MZ) B cells in acute and chronic HIV-1 infection. A substantial fraction of naive and MZ B cells exhibit down-regulated
CD21 levels and diminished response to B cell receptor (BCR)–dependent stimulation. Compared with CD21pos subsets, the
CD21neg naive and MZ B cells differ in the expression of chemokine receptors and activation markers. Effective antiretroviral
treatment normalizes peripheral naive and MZ B cell populations. Our results emphasize a more widely spread impairment of
B cells in HIV-1 infection than previously appreciated, including antigen-inexperienced cells. This highlights the importance of
monitoring functional capacities of naive B cells in HIV-1 infection, as exhausted CD21neg naive B cells may severely impair
induction of novel B cell responses.
Introduction
HIV-1 infection is accompanied bymassive bystander activation,
impairing many components of the immune system, including
B cells (Bangs et al., 2006; Haas et al., 2011). These perturbations
lead to a general deficiency in mounting antibody respon-
ses against pathogens and vaccines during HIV-1 infection
(Malaspina et al., 2005; Titanji et al., 2006; Fritz et al., 2010;
Kerne´is et al., 2014). Neutralizing antibodies against HIV-1
emerge within months after infection but are subject to rapid
escape by the virus (Wei et al., 2003; Bunnik et al., 2008). In a
minority of HIV-1–infected patients, continuous virus and an-
tibody coevolution leads to the development of antibodies with
improved potency and breadth, so-called broadly neutralizing
antibodies (bnAbs; Moore et al., 2012; Liao et al., 2013). What
effect B cell perturbations have on the development of HIV-1
neutralizing antibodies and bnAbs remains uncertain (Derdeyn
et al., 2014; Meffre et al., 2016). While a number of factors have
been suggested to shape the development of bnAbs (Doria-Rose
et al., 2010; Moore et al., 2015; Rusert et al., 2016; Kadelka et al.,
2018; Subbaraman et al., 2018), disturbed functionality of the
B cell population may be an additional reason that bnAbs de-
velop late and only in a fraction of individuals (Derdeyn et al.,
2014; Meffre et al., 2016). Likewise, certain alterations of the
immune environment that also affect B cells may foster bnAb
evolution (Kadelka et al., 2018; Subbaraman et al., 2018).
Perturbations of B cells in HIV-1 infection are characterized
by increased frequencies of activated (AM) and exhausted
tissue-like (TLM)memory B cells. These cells differ from resting
(RM) and intermediate (IM) memory B cells by the loss of
complement receptor 2 (CD21) expression; distinct expression of
activation, inhibitory, and chemokine receptors; and diminished
response to stimulation (Moir et al., 2008; Moir and Fauci, 2013;
Kardava et al., 2014). Beyond shifts within memory B cells, in-
creased frequencies of plasmablasts and transitional B cells have
been observed (Malaspina et al., 2006; Buckner et al., 2013). A
substantial proportion of HIV-1–specific memory B cells are
found within TLM B cells (Kardava et al., 2014). This suggests
that a large fraction of HIV-1–specific B cells are exhausted and
impaired in generating effective high-affinity antibody re-
sponses (Kardava et al., 2014; Meffre et al., 2016).
De novo antibody responses are diminished in HIV-1 infec-
tion (Malaspina et al., 2005; Titanji et al., 2006; Fritz et al., 2010;
Kerne´is et al., 2014). We therefore hypothesized that HIV-1 may
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also impact antigen-inexperienced naive B cells. We applied
high-dimensional flow cytometry to comprehensively assess the
longitudinal phenotypic and functional dynamics of B cell sub-
sets in blood during acute and chronic HIV-1 infection and
probed the potential of antiretroviral therapy (ART) in reversing
these alterations. We demonstrate that CD21neg naive and
CD21neg MZ B cell subsets emerge early during acute HIV-1 in-
fection, increase in frequency during chronic infection, and
regress upon ART. The phenotype and functionality of CD21neg
naive and CD21neg MZ B cells resembles anergic polyreactive
naive B cells described in autoimmunity (Rakhmanov et al.,
2009; Isnardi et al., 2010; Tipton et al., 2015; Flint et al., 2016).
This highlights the need to investigate their role in the devel-
opment of polyreactive HIV-1–specific antibody responses
(Mouquet et al., 2010; Liu et al., 2015). Importantly, our findings
emphasize the profound influence of HIV-1 replication at early
stages of B cell maturation that result in the induction of an
anergic state. This may be a driving force of the delayed and
impaired antibody responses observed in HIV-1 infection.
Results
Longitudinal changes of major B cell subsets in HIV-1 and the
impact of ART
To investigate if HIV-1 induces widespread perturbation of
B cells, we analyzed peripheral blood from HIV-1–infected in-
dividuals enrolled in the Zurich Primary HIV Infection Study
(ZPHI) using high-dimensional flow cytometry. Patients were
stratified into two groups according to the time point of ART
initiation. In the early ART initiation group, ART was initiated
during acute infection, followed by a period of ART interruption
during chronic phase. In the late ART initiation group, ART was
delayed and initiated during chronic infection (Fig. 1 A and
Tables S1 and S2). For each HIV-1–infected individual, four time
points encompassing (i) acute infection, (ii) 1 yr and (iii) 2 yr of
chronic infection, and (iv) 1 yr on ART were analyzed. Table S2
describes the selection of early and late ART group samples for
the various analyses. Healthy controls from single sampling time
points were used as baseline.
We used 16-color flow cytometry to definemain B cell subsets
(transitional, naive, marginal zone [MZ], memory B cells, and
plasmablasts) and memory B cell subsets in blood (Fig. S1, A and
B; Liechti et al., 2018a). By monitoring changes in B cell subsets
during HIV-1 infection, we found increased frequencies of
transitional B cells and plasmablasts in HIV-1–infected in-
dividuals (n = 19) compared with healthy donors (n = 29; Fig. 1 B).
In contrast, patients on ART exhibited significantly (P < 0.01)
higher frequencies of naive B cells than during their acute phase.
Importantly, ART treatment reversed the elevated frequencies
of transitional B cell and plasmablasts to healthy donor levels.
In accordance with earlier reports (Moir et al., 2008, 2010),
memory B cell subsets were distorted, showing increased fre-
quencies of AM and TLM B cells in contrast to decreased levels of
IM and RM B cells during acute and chronic HIV-1 infection
(Fig. 1 C). ART did not restore these subsets to levels observed in
healthy individuals (Fig. 1 C; Moir et al., 2010). Loss of CD21
signifies AM and TLM B cells in HIV-1 infection (Moir et al.,
2008; Moir and Fauci, 2013). Strikingly, we also observed in-
creased frequencies of CD21neg naive andMZ B cells (Fig. 1 D and
Fig. S1 B). Successful ART restored CD21pos subset levels, albeit
not to frequencies observed in healthy donors. The influence of
HIV-1 infection on antigen-inexperienced B cells demonstrated
by the loss of CD21pos naive and MZ B cells is highly intriguing
and underscores the general impact of HIV-1 infection on B cells.
We next assessed the potential influences of ART initiation
and disease course, analyzing B cell subsets in the early ART and
late ART groups (Fig. S1, B–D). With the exception of MZ B cell
levels, which were lower in the acute-phase sampling time point
in the early ART initiation group, no differences between the
two treatment groups were observed (Fig. S2, A–C). Healthy
controls (n = 29) and individuals from the late ART initiation
group (n = 8) showed similar MZ B cell levels, while patients
within the early ART initiation group (n = 11) had reduced MZ
B cell frequencies (Fig. S2 A). Interestingly, samples we had
available for the early ART group were derived sooner after
infection compared with the late ART group (Tables S1 and S2).
Collectively, this strongly suggests that MZ B cells are disturbed
very early during acute HIV-1 infection but that their frequency
rapidly normalizes (Fig. S2 D).
Assessing B cell subset signatures
We next performed a signature analysis to explore if HIV-1 in-
fection leads to the formation of distinct phenotypic patterns.
We focused therein on distinct subsets and thus did not include
total naive, MZ, and memory B cells in the analysis. Data on
B cell subsets from healthy controls (n = 29) and HIV-1–infected
individuals (n = 19 for acute time point; n = 21 for chronic 2 yr
time point and after 1 yr of ART; Fig. 1, B–D) were analyzed using
the dimensionality reduction algorithm tSNE (t-distributed
stochastic neighbor embedding; Fig. 1 E). The tSNE-based B cell
signatures of viremic samples from HIV-1 patients (acute and
chronic time points) proved distinct from signatures observed
for healthy controls and samples after prolonged ART high-
lighting the influence of HIV-1 replication (Fig. 1 E).
Four of the chronic HIV-1–infected individuals (Z23, Z32,
Z58, and Z92) displayed patterns that closely matched healthy
controls. This reflected their overall low HIV-1 progression as
evidenced by lower viral loads, higher CD4 counts, and lower
plasma IgG levels (Fig. 1, E and F). We next probed the impact of
viral load, CD4 count, and plasma IgG levels on the emergence of
CD21neg naive and CD21neg MZ B cells. We observed no direct
link between levels of CD21neg naive B cells and these parameters
in acute or chronic infection (Fig. 2). However, the increase of
CD21neg MZ B cells was strongly linked with decreasing CD4
T cell counts and increases in viral load, but not plasma IgG
levels during the chronic phase (Fig. 2). We next explored as-
sociations between CD21neg naive and CD21neg MZ B cells and the
HIV-1–specific IgG1 response in a subset of patients (acute, n = 13;
chronic 2 yr, n = 14). IgG1 reactivity with 13 HIV-1 antigens was
measured in a multiplex binding assay as recently described
(Kadelka et al., 2018; Liechti et al., 2018b). Interestingly, CD21neg
naive B cells, but not CD21neg MZ B cells, correlated positively
with HIV-1–specific antibody responses to eight antigens in
acute and two antigens in chronic infection (Fig. S3).
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Figure 1. B cell subset changes during HIV-1 infection. (A) Schematic overview of the longitudinal HIV-1 study (see Materials and methods).
(B–D) Frequencies of main B cell subsets (B), memory B cell subsets (C), and CD21neg naive and CD21neg MZ B cells (D) from healthy donors (n = 29) and
HIV-1–infected patients (n = 19) at acute and chronic disease stages and after 1 yr on ART. P values were derived from linear mixed-effect models with Tukey’s
method for multiple comparison (see Materials and methods). (E) Left: Two-dimensional tSNEmap of healthy donors (n = 29) and patients (n = 19 for acute and
n = 21 for ART 1-yr and chronic 2-yr time points) based on the z-scores of the frequencies of B cell subsets shown in B–D (see Materials and methods). Right:
Stratification of the same tSNE map by time point and healthy controls. The red dashed line separates cluster I (bottom) and II (top). (F) Clinical parameters of
chronic HIV-1–infected individuals (n = 20 for CD4 counts and n = 21 for plasma IgG and viral load) in cluster I and cluster II (from E) compared using
Mann–Whitney U test. Data represent a single measurement from each patient time point assessed. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Error bars in B–D and F indicate SD.
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Our analysis did not have the statistical power to define
antigen-specific IgG patterns and dependencies. However, the
observation that B cell subset– and disease stage–driven effects
on IgG1 levels can occur highlights the need to resolve the impact
on responses to different HIV-1 antigens as well as neutralizing
antibodies in forthcoming studies.
Differential expression of chemokine receptors and IL-21R on
CD21neg and CD21pos naive and MZ B cell subsets
CD21neg B cells in autoimmune and chronic viral diseases display
altered chemokine and cytokine receptor expression profiles
(Rakhmanov et al., 2009; Isnardi et al., 2010; Saadoun et al.,
2013; Moir and Fauci, 2014; Tipton et al., 2015). To explore if
this extends to naive and MZ B cell subsets, we analyzed the
expression of CCR7, CXCR3, CXCR4, CXCR5, and IL-21R in
healthy (n = 29) and chronically HIV-1–infected (n = 21) donors
(Figs. 3 and 4). CD21neg naive B cells generally displayed de-
creased frequencies of CCR7, CXCR5, and IL-21R and an in-
creased frequency of CXCR3-expressing cells (Fig. 3, A and B).
Receptor levels on these subsets differed accordingly (Fig. 4, A
and B). With the exception of IL-21R, the same alterations in
expression profiles were observed between CD21neg and CD21pos
MZ B cells (Fig. 3 B and Fig. 4, A and B). IL-21R was expressed at
higher levels and on more cells within the CD21neg MZ B cell
subset in chronically HIV-1–infected, but not healthy, in-
dividuals. The divergent expression dynamics of IL-21R in
CD21neg naive and CD21neg MZ B cells in HIV-1 infection is
intriguing and may reflect differential dependence on IL-21R
signaling.
HIV-1 infection was signified by a decrease in CCR7 and
CXCR5 and an increase in CXCR3 and IL-21R-expressing CD21neg
and CD21pos naive B cell subsets (Fig. 3 C). A similar pattern was
observed for MZ B cells, with the exception of CCR7 expression,
which was elevated in CD21neg MZ B cells during HIV-1 infection
(Fig. 3 C). Comparison of expression levels in CD21neg and
CD21pos naive and CD21neg and CD21pos MZ B cells between
healthy and chronic HIV-infected individuals confirmed these
observations (Fig. 4, B and C).
Healthy individuals displayed fewer CXCR4-expressing cells
among CD21neg naive and MZ B cells compared with the corre-
sponding CD21pos subsets (Fig. 3 B). This pattern differed in
chronic HIV-1 infection. CD21neg and CD21pos naive B cells ex-
pressed CXCR4 at similar frequencies, and the contingency of
CXCR4pos CD21neg MZ B cells was higher than in CD21pos MZ
B cells (Fig. 3 B). In line with this, we observed an overall in-
crease in CXCR4 expression in CD21neg compared with CD21pos
B cell subsets (Fig. 4, B and C). Of note, CD21neg naive and
CD21neg MZ B cells of HIV-1–infected donors displayed increased
CD19 expression levels (Fig. 4, B and C), as described for ex-
hausted B cells in autoimmunity (Rakhmanov et al., 2009).
We next explored longitudinal changes in phenotypes of
CD21neg naive and CD21neg MZ B cells upon prolonged exposure
to HIV-1, comparing subset patterns in the early (n = 11) and late
(n = 8) ART initiation groups (Fig. 5 A). The most pronounced
Figure 2. Correlation of CD21neg naive and CD21neg MZ B cells with clinical parameters. Linear regression of CD21neg naive and CD21neg MZ B cells with
CD4 counts, viral load, and plasma IgG concentration in acute and chronic HIV-1 infection. Sample size N, coefficient of determination r2, and P values are
indicated. P < 0.05 was considered statistically significant and is highlighted in red. Data represent single measurements from each patient time point assessed.
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pattern changes were observed among the early ART initiation
group during continued virus replication (Fig. 5, A and B). This
again reflects an impact of continued virus replication on the
phenotype of CD21neg naive B cells and MZ cells. Overall, we
observed more variation among B cell phenotypes in the early
ART group, where individuals went through chronic infection
stages only upon ART cessation. In contrast, uninterrupted virus
replication, as monitored in the late ART initiation group, ap-
peared to lead to a set-point level in B cell perturbation that late
ART could not fully reverse. Collectively, our data therefore
reveal distinct phenotypes of CD21neg naive and CD21neg MZ
B cells, which are differentially impacted by HIV-1 infection.
CD21neg naive B cells form a heterogeneous population
To obtain a complete overview of the subset heterogeneity, we
subjected our data to an unsupervised spanning-tree progres-
sion analysis of density-normalized events (SPADE) clustering
analysis (Qiu et al., 2011), followed by Ward hierarchical clus-
tering. We focused the analysis on CD21neg naive B cells, because
the numbers of CD21neg MZ B cells were too low to allow reliable
clustering. Longitudinal samples (acute, chronic 1 yr, chronic
2 yr, and ART 1 yr) of 17 HIV-1–infected patients and 15 healthy
donors were assessed. The SPADE analysis provided an in-
triguing insight into the high diversity within CD21neg naive
B cells (Fig. 6, A and B). CXCR4was not chosen for clustering due
Figure 3. Phenotype of CD21neg naive and CD21neg MZ B cells. (A) Expression of CCR7, CXCR3, CXCR4, CXCR5, and IL-21R on CD21neg and CD21pos naive
and CD21neg and CD21pos MZ B cells and FMO controls are shown for a representative healthy control donor. Numbers in dot plots indicate percentage of gated
population. (B) Comparison of frequencies of CD21neg (gray open circle) and CD21pos (black closed circle) naive and MZ B cells expressing CCR7, CXCR3, CXCR4,
CXCR5, and IL-21R in healthy (n = 29) and HIV-1–infected (chronic 2 yr, n = 21) donors. (C) Differences of the same markers between healthy donors
(n = 29, n = 14 for IL-21R and CXCR5) and chronically HIV-1–infected donors (chronic 2 yr, n = 21, n = 19 for IL-21R and CXCR5) are shown. Data
represent single measurements from each patient time point assessed. Comparison between CD21neg and CD21pos naive and CD21neg and CD21pos MZ
B cells within the same individual was done using Wilcoxon signed rank test and between healthy and HIV-1–infected individuals using Mann–Whitney
U test. ND, comparison not performed (see Materials and methods). **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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to staining variability across samples (see Materials and meth-
ods). Likewise, owing to its unimodal expression pattern, CD19
was not selected for cluster formation. However, some expres-
sion profiles of markers used for clustering (for example, high
levels of CXCR3 in Ward clusters 3, 4, and 8) were associated
with elevated levels of CD19 and CXCR4 and highlighted some
degree of redundancy of thesemarkers (Fig. 6, A–C). A drawback
of clustering algorithms is the need for overclustering to define
rare cell subsets (Diggins et al., 2015; Nowicka et al., 2017). We
thus subsequently merged SPADE clusters with similar median
Figure 4. CD21neg naive and CD21neg MZ B cells exhibit distinct expression levels of chemokine receptors IL-21R and CD19. (A) Histogram overlays of
CCR7, CXCR3, CXCR4, CXCR5, IL-21R, and CD19 expression on CD21neg and CD21pos naive (dark red and red, respectively) and CD21neg and CD21pos MZ B cells
(dark blue and blue, respectively) from a chronic HIV-1–infected patient are shown. Where applied, FMO controls (gray) from a healthy donor are depicted.
Numbers in histogram overlay indicate the MFI. (B) Differences of MFI between CD21neg and CD21pos naive (top row) and CD21neg and CD21pos MZ B cells
(bottom row) in healthy controls (n = 29, n = 14 for IL-21R and CXCR5) and HIV-1–infected patients (chronic 2 yr, n = 21, n = 19 for IL-21R and CXCR5) are shown
for CCR7, CXCR3, CXCR4, CXCR5, IL-21R, and CD19. (C)MFI fold-change ratio between CD21neg and CD21pos naive or CD21neg and CD21pos MZ B cells for CCR7,
CXCR3, CXCR4, CXCR5, IL-21R, and CD19 are shown and compared between healthy controls (n = 29) and chronically HIV-1–infected patients (n = 21). Data
represent single measurements from each patient time point assessed. Wilcoxon signed rank test was used to compare CD21neg and CD21pos naive and CD21neg
and CD21pos MZ B cells within the same individual, and Mann–Whitney U test to compare differences between healthy controls and chronically HIV-1–infected
patients. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Error bars indicate SD.
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expression levels using Ward’s hierarchical clustering method
(Ward, 1963) and defined 10 distinct clusters (Fig. 6 C). To verify
the validity of the Ward clustering, we performed a manual
analysis of these 10 Ward clusters, which confirmed distinct
expression patterns for the majority of them (Fig. 6 C). Of note,
some Ward clusters shared common phenotypic characteristics
such as high CXCR3 levels (clusters 2, 3, and 8), high IL-21R
levels (clusters 4, 6, and 9), or high CCR7 and CXCR5 levels
(clusters 7, 8, and 10; Fig. 7 A).
We next analyzed the longitudinal dynamics of these clusters
during HIV-1 infection by stratifying the early and late ART
initiation groups and comparing them with healthy controls
(Fig. 7, A and B). Overall, Ward clusters of HIV-1–infected and
healthy controls were similar. Of note, as observed in the
manual analysis (Fig. 6), longitudinal changes of the identified
Ward subsets were apparent only in the early ART group and
restricted to clusters 4, 7, and 10 (Fig. 7 B). Cluster 4 was asso-
ciated with higher IL-21R and CXCR3 expression, whereas
clusters 7 and 10 were associated with high expression of CCR7
and CXCR5 (Fig. 7 A). The longitudinal changes observed for
clusters 4, 7, and 10 were most pronounced at 2 yr of chronic
infection, the latest time point measured in our study, empha-
sizing the progressive effect of prolonged HIV-1 infection.
Concomitant with decreased CCR7 levels, an increase in cell
subsets that display inflammatory markers including CXCR3,
CXCR4, and IL-21R as well as elevated levels of CD19 occurred. Of
Figure 5. Longitudinal analysis of phenotypic markers on CD21neg naive and CD21neg MZ B cells. (A) Longitudinal analysis of percentage of CD21neg naive
and CD21neg MZ B cells expressing CCR7, CXCR3, CXCR4, CXCR4, and IL-21R. HIV-1–infected patients were split into an early ART initiation group (closed
circles; n = 11) and a late ART initiation group (open circles, n = 8). (B) Expression levels of CD19 on CD21neg naive and CD21neg MZ B cells for the same samples
are depicted. Data represent single measurements from each patient time point assessed. P values were derived from linear mixed-effect models with Tukey’s
method for multiple comparison (see Materials and methods). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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Figure 6. Computational clustering algorithm SPADE reveals heterogeneity of CD21neg naive B cells in chronic HIV-1 infection. (A) SPADE trees from
combined CD21neg naive B cells of chronic (n = 17, chronic 2 yr) HIV-1–infected patients are shown. Expression levels of markers used for clustering (see
Materials andmethods) are depictedwithin dot of each cluster. Dot sizes correspond to cell counts per cluster. (B) Expression of CXCR4 and CD19 (not used for
clustering) within the SPADE tree. (C) Heatmap with expression profile of SPADE clusters ordered using Ward’s hierarchical clustering. Similar SPADE clusters
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note, we also observed intriguing interdependencies between
phenotypic marker expression and clinical parameters in naive
and MZ B cell subsets in chronic HIV-1–infected patients (chronic
2 yr time point). CD21pos naive B cells showed a positive correlation
of CD19 levels with both CXCR3 and IL-21R, while CD19 correlated
solely with CXCR4 in CD21neg naive B cells (Fig. 7 C). Collectively,
the side-by-side comparison of healthy and HIV-1–infected donors
validated that the defined Ward clusters represent common naive
andMZ B cell subsets and allowed the definition of distinct subsets
and markers affected by HIV-1 infection.
CD21neg naive and CD21neg MZ B cells display markers linked
with distinct functional properties
Anergic naive B cells compose ≤30% of naive B cells in healthy
individuals and increase in autoimmunity and viral diseases
(Duty et al., 2009; Rakhmanov et al., 2009; Isnardi et al., 2010;
Tipton et al., 2015; Flint et al., 2016). These cells exhibit low IgM
levels (Duty et al., 2009; Qua´ch et al., 2011) and reduced ex-
pression of CD21 (Rakhmanov et al., 2009; Qua´ch et al., 2011;
Tipton et al., 2015). Autoreactivity is enriched in IgMlow naive
B cells, and reduced responsiveness of autoreactive B cells to
antigen-dependent stimulation is likely an important mecha-
nism of peripheral tolerance (Qua´ch et al., 2011). To probe if
CD21neg naive and CD21neg MZ B cells share similarities with
anergic B cells, we analyzed IgM expression in a subset of
chronically HIV-1–infected individuals from the longitudinal
cohort (n = 6) and healthy controls (n = 29; Fig. 8, A and B). CD95
and FcRL4 expression was recorded, as elevated expression of
these markers defines B cell activation and exhaustion (Moir
et al., 2008; Sciaranghella et al., 2013; Portugal et al., 2015).
Frequencies of IgMlow cells were generally higher in CD21neg
compared with CD21pos naive B cells, as described (Qua´ch et al.,
2011; Fig. 8 C). However, decreased frequencies of IgMlow cells in
both subsets were observed in HIV-1 infection (Fig. 8 B), while
IgMlow frequencies of MZ B cells were unchanged (Fig. 8, B and
C). Elevated frequencies of IgMlow cells suggest that CD21neg
naive B cells indeed comprise a higher proportion of anergic and
autoreactive B cells.
In line with an activated state, CD95 and FcRL4 were gen-
erally expressed at higher levels on CD21neg subsets (Fig. 8 C).
HIV-1 infection led to increased CD95 expression on naive and
MZ B cells across CD21 subsets, which was most pronounced in
acute infection (Fig. 8 B). The same pattern was observed for
FcRL4 expression, with the exception of CD21pos naive B cells,
where no alteration in response to HIV-1 infection was evident
(Fig. 8 B). Importantly, ART successfully reduced CD95 and
FcRL4 to healthy donor levels in all subsets. This mirrored the
effects observed for memory B cell subsets (Fig. 8, D and E).
Except for IM B cells, CD95 and FcRL4 were elevated and
reverted to healthy donor levels upon prolonged ART (Fig. 8,
D and E).
Collectively, CD21neg naive and CD21neg MZ B cells showed
features of recent activation (Fig. 8). In healthy donors (n = 29),
this was accompanied with increased proliferation (Ki-67 ex-
pression) compared with the CD21pos subsets (Fig. 9, A and B).
Chronic HIV-1 infection (n = 21) increased Ki-67 expression in
CD21pos subsets over healthy donor levels comparable to the
level in CD21neg subsets (Fig. 9 B).
Increased expression of CD95 suggests that CD21neg naive and
CD21neg MZ B cells may be sensitive to extrinsic proapoptotic
signals. We therefore investigated ex vivo whether these cells
are apoptotic. Higher frequencies of cleaved caspase 3pos An-
nexin Vpos apoptotic cells were observed in CD21neg naive and
CD21neg MZ B cells of healthy (n = 10) and chronically HIV-
1–infected (n = 10) individuals (Fig. 9, C and D). Notably,
CD21neg naive B cells from HIV-1–infected people had more ap-
optotic cells than in healthy donors, emphasizing that chronic
HIV-1 infection drives apoptosis in naive B cells. We conclude
that CD21neg subsets of naive and MZ B cells reflect a general
state of activation, proliferation, and exhaustion at the inves-
tigated time point. CD21neg naive B cells in particular
include phenotypes linked with anergic, autoreactive, and
apoptotic cells.
Reduced responsiveness of CD21neg naive and CD21neg MZ
B cells
To probe if CD21neg naive and CD21neg MZ B cells are indeed
anergic, we next tested their potential to respond to BCR-
dependent stimulation. We applied Phosflow (Schulz et al.,
2012) to measure tyrosine phosphorylation in untreated or
anti-IgA/-IgM/-IgG stimulated naive and MZ B cells. Memory
B cell subsets (IM, RM, AM, and TLM) were analyzed in com-
parison (Fig. 10, A–D). RM cells, known to be in a quiescent state,
had the highest potential to respond to stimulation, while the
exhausted TLM cells were the least responsive to BCR cross-
linking (Fig. 10, B–D). Of note, basal phosphorylation levels
were highest in AM cells, in line with a recent stimulation
in vivo (Fig. 10, B–D).
CD21neg MZ B cells of healthy individuals (n = 10) and CD21neg
naive and CD21neg MZ B cells of HIV-1–infected individuals
(n = 10) showed increased basal phosphorylation over the cor-
responding CD21pos subsets (Fig. 10 C). This indicates that CD21neg
naive and CD21neg MZ B cells had undergone recent activation-
induced phosphorylation. Reactivity to BCR stimulation was
lower in CD21neg naive B cells compared with CD21pos naive
B cells, suggesting that these cells had reached an anergic state
(Fig. 10, C and D). Based on absolute expression levels (mean
fluorescence intensity [MFI]), CD21neg and CD21pos MZ B cells
showed an identical capacity to react to BCR triggering in
healthy donors, but the response of CD21neg MZ B was reduced
in HIV-1 infection (Fig. 10 C). However, considering fold dif-
ference between basal phosphorylation levels and levels upon
are merged in 10Ward clusters. Dendrogram is colored according to the cutoff used to defineWard clusters. CD19 and CXCR4 expression profile of each SPADE
cluster is shown on the right. (D) Flow cytometry analysis of Ward clusters from all combined chronic 2-yr samples (n = 17) used for SPADE/Ward clustering.
CD21neg naive B cells (red) are overlaid on total CD21neg B cells (gray). Total CD21neg B cells are shown in the first column. Data represent single measurements
from each patient time point assessed.
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Figure 7. Longitudinal ward cluster dynamics in HIV-1 infection. (A) Expression levels of CCR7, CXCR3, CXCR4, CXCR5, IL-21R, and CD19 on Ward clusters
from HIV-1–infected patients (n = 17; chronic 2 yr) are shown as z-score of arcsinh-transformed MFI values normalized between 0 and 1 (see Materials and
methods). (B) Comparison of Ward cluster frequencies between healthy donors (black dots, n = 15) and acute (blue), chronic 1 yr (light red), chronic 2 yr (dark
red), and ART 1 yr (gray) time point of HIV-1–infected patients, which were separated into early (closed dots, n = 9) and late (open circles, n = 8) ART initiation
groups. P values were derived from linear mixed-effect models with Tukey’s method for multiple comparison (see Materials and methods). *, P < 0.05; **, P <
0.01; ***, P < 0.001. (C) Spearman correlation of expression of CCR7, CXCR3, CXCR4, CXCR5, and IL-21R in addition to log-transformed viral load, plasma IgG
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stimulation instead of MFI revealed that a lower reactivity of
CD21neg MZ B cells was also prevalent among healthy donors
(Fig. 10 D).
Overall, we observed an impaired stimulation potential in
memory B cell subsets and MZ B cells with an activated phe-
notype (AM, TLM, and CD21neg MZ B cells) but not in resting
cells (RM, IM, and CD21pos MZ B cells) in HIV-1 infection (Fig. 10
E). The notable exception was the CD21neg naive B cell subset,
which showed overall reduced responsiveness that was not
influenced by HIV-1 infection (Fig. 10 E).
Discussion
Alterations of the B cell compartment induced byHIV-1 infection
are characterized by increased levels of transitional B cells and
plasmablasts and skewing of memory B cells toward activated
and exhausted phenotypes (Moir et al., 2008, 2010; Moir and
Fauci, 2013). Whether these perturbations extend to other B cell
subsets has not been systematically investigated. Using high-
dimensional flow cytometry, we define here B cell signatures
associated with progressing HIV-1 infection that reveal a severe
impact on naive and MZ B cells.
Increased frequencies of CD21neg memory B cells are a
hallmark of HIV-1 infection (Moir et al., 2008, 2010). Here we
report that a substantial proportion of naive and MZ B cells
also lack CD21 in chronic HIV-1 infection (Fig. 1 D). Intrigu-
ingly, CD21neg cells constitute only a minor fraction of naive
B cells in healthy individuals, but increased frequencies are
described in common variable immunodeficiency and auto-
immune disorders (Rakhmanov et al., 2009; Isnardi et al.,
2010; Tipton et al., 2015; Flint et al., 2016). These cells ex-
press high levels of activation markers such as CD95 and ex-
hibit impaired response to activation in vitro (Rakhmanov
et al., 2009; Isnardi et al., 2010). As we demonstrate here,
CD21neg naive B cells in HIV-1 infection show high similarities
with CD21neg naive B cells described in autoimmune diseases.
Resolving the origin and fate of these cells, whether they
evolve from classical CD21pos naive B cells upon activation or
have individual development paths, will be of interest in HIV-1
infection and beyond.
Aberrant MZ B cell responses associated with a CD21neg
phenotype as we describe have not been intensively studied
(Terrier et al., 2011). Our detailed phenotypic analyses provide
important insights into the properties of CD21neg MZ B cells,
which we found share many features with CD21neg subsets of
naive and memory B cells. The strong association of CD21neg MZ
B cells with CD4 counts and viral load in chronic HIV-1 infection
suggests that their activation and exhaustion state is linked with
virus-induced immune activation (Fig. 2). In contrast, CD21neg
naive B cells are not associated with these clinical factors, sug-
gesting that this subset is steered by other factors during HIV-1
infection. Our findings highlight the need for a systematic in-
vestigation of the triggers that lead to CD21neg MZ and CD21neg
naive B cell emergence and their consequence for consecutive
immune responses.
MZ B cells are involved in IgM responses and, owing to their
low potential to undergo class-switch recombination, likely play
a minor role in IgG responses (Kruetzmann et al., 2003; Seifert
et al., 2015). In line with this, we found HIV-1–specific IgG1 re-
sponses to correlate with CD21neg naive but not CD21neg MZ
B cells. CD21neg naive B cells were linked with HIV-1–specific
IgG1 responses, particularly in the acute phase, and thus may
impact de novo responses to HIV-1. Persistent antigen exposure
in chronic HIV-1 infection drives the expansion of large clonal
families of B cells (Liao et al., 2013; Doria-Rose et al., 2014),
which may constrict the impact on the de novo responses and
dependence on naive B cells. Delineating the contribution of
CD21neg naive B cells in the HIV-1–specific antibody response in
forthcoming studies will be of importance to understand their
role in shaping antibody responses to HIV-1 at different disease
stages.
HIV-1 infection is associated with impaired antibody re-
sponses against other pathogens and vaccines (Titanji et al.,
2006; Fritz et al., 2010; Kerne´is et al., 2014). IgM responses to
vaccination appear to be more severely impaired by progressed
HIV-1 infection compared with IgG (Fritz et al., 2010). This
suggests that de novo induction of IgM by naive B cells, but not
reactivation of IgG from memory B cells, is affected (Fritz et al.,
2010; Pape et al., 2011). As we show here, a large pool of naive
B cells in HIV-1 infection is anergic, which may be a main cause
of the impaired antibody responses (Fig. 10, A–C).
Immune responses against bacterial polysaccharides are
largely dependent on MZ B cells, and splenectomy has been
linked with higher risk of infections with bacterial pathogens
such as Streptococcus pneumoniae (Kruetzmann et al., 2003; Weill
et al., 2009). Infections associated with dramatic alterations of
the B cell compartment, such as HIV-1, show reduced responses
against polysaccharide-based vaccines and are associated with
increased risk of bacterial coinfections. However, the reasons
for this defect have thus far been unclear (Zhang et al., 2015;
Sadlier et al., 2016). The extensive emergence of nonresponsive
CD21neg MZ B cells that we document here provides a plausible
cause for the impaired responses.
The dysfunction of CD4 T cells induced by HIV-1 severely
impacts B cell responses (Day et al., 2006; Walker and
McMichael, 2012). CD4 follicular helper T (TFH) cells are im-
paired in their ability to provide B cell help (Cubas and Perreau,
2014). Increased levels of PD-L1 on B cells drive dysfunction of
TFH cells. Thus, defects of T and B cells directly affect each other,
and suboptimal TFH cell help may drive the exhaustion of naive
and memory B cells (Cubas et al., 2013). It will thus be important
to establish in forthcoming studies whether dysfunctions of the
levels (mg/ml), and CD4 counts from HIV-1–infected individuals (chronic 2 yr; see also Table S2) for CD21neg and CD21pos naive and CD21neg and CD21pos MZ
B cells. P values from Spearman correlation were considered significant when P < 0.05 and are colored orange for positive and dark blue for negative cor-
relation. P values between 0.05 and 0.06 are colored yellow for positive and light blue for negative correlation and highlight trends. Nonsignificant values are
shown in gray. Data represent single measurements from each patient time point assessed.
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T cell compartment drive the emergence of CD21neg naive and
CD21neg MZ B cells during HIV-1 infection.
Interestingly, poly- and autoreactive BCRs are enriched
within CD21neg B cells in healthy individuals and autoimmune
diseases (Isnardi et al., 2010; Saadoun et al., 2013). Their pro-
nounced phenotypic similarity with B cells in autoimmunity
raises the possibility that CD21neg naive B cells in HIV-1 may also
be enriched for polyreactivity. Investigations of large patient
Figure 8. CD21neg naive and CD21neg MZ B cells are highly activated. (A) Example of IgM, CD95, and FcRL4 staining for a HIV-1–infected donor (chronic
2 yr). Top row: IgM and IgD expression on CD21neg naive and CD21neg MZ B cells (red) overlaid on total B cells (gray). Bottom rows: CD95 and FcRL4 expression
on CD21pos and CD21neg naive and CD21pos and CD21neg MZ B cells. (B) IgM, CD95, and FcRL4 expression dynamics of the same subsets from healthy controls
(n = 29) and HIV-1–infected patients (n = 6) at acute, chronic 2 yr, and ART 1 yr time points. (C) Comparison of IgM, CD95, and FcRL4 expression on B cell
subsets in healthy subjects (n = 29) and chronic HIV-1–infected patients (n = 6). Comparison between CD21neg and CD21pos naive and CD21neg and CD21pos MZ
B cells within the same individual was done using Wilcoxon signed rank test. (D) Flow cytometry dot plots of CD95 and FcRL4 expression on IM, RM, AM, and
TLM B cells for HIV-1–infected patient (chronic 2 yr). (E) Comparison of CD95 and FcRL4 expression on memory B cell subsets. Analysis was performed on
healthy controls (n = 29) and different time points of HIV-1–infected patients (n = 6). P values in B and E were derived from linear mixed-effect models with
Tukey’s method for multiple comparison (see Materials and methods). P < 0.05 was considered statistically significant. *, P < 0.05; **, P < 0.01; ***, P < 0.001;
****, P < 0.0001. Data represent single measurements from each patient time point assessed. Numbers in dot plots in A and D indicate percentage of gated
population. Error bars in B and E depict minimum to maximum range.
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cohorts will be needed to establish if polyreactivity is indeed
common among CD21neg naive B cells and if this is the under-
lying cause of the emergence of autoantibodies in HIV-1 infec-
tion (Shirai et al., 1992; Moir and Fauci, 2009).
Poly- and/or autoreactivity is a common feature of many
neutralizing antibodies and bnAbs in HIV-1 infection and con-
tributes to their neutralization activity (Haynes et al., 2005;
Mouquet et al., 2010; Liu et al., 2015). Elicitation of polyreactive
bnAbs requires a concerted action to overcome immune toler-
ance mechanisms and may thus be rare (Verkoczy et al., 2010,
2011; Zhang et al., 2016). Autoreactive CD21neg naive and CD21neg
MZ B cells could be envisaged to play a role in the elicitation of
potent HIV-1–specific bnAbs. Deciphering their role in bnAb
induction will be important to potentially harness these cells for
vaccine induction of bnAbs.
A large fraction of plasmablasts and IgMpos memory B cells in
the periphery of systemic lupus erythematosus (SLE) patients
derive from activated naive B cells with similar features as the
CD21neg naive B cells described herein (Tipton et al., 2015). These
activated naive B cells in SLE showed increased polyreactivity, a
remarkable frequency of somatic hypermutation, and the ability
to expand resulting in large clonal families. Whether these cells
participate in germinal center reaction or are engaged in ex-
trafollicular pathways still need to be resolved, but available data
highlight that activated CD21neg naive B cells can undergo BCR
affinity maturation and develop into large clusters of antibody-
secreting effector cells in SLE. To explore this potential pathway
in HIV-1 infection, dedicated studies are needed to dissect
whether CD21neg naive B cells in HIV-1 infection have analogous
capacities. The severe exhaustion and anergic state of these cells
in HIV-1 infection, however, may be a limitation that needs to be
understood to resurrect the functional properties of this cell
population.
Combining high-dimensional flow cytometry with unsuper-
vised clustering analysis allowed us to elucidate the phenotypic
diversity within CD21neg naive B cells. The analysis revealed 10
phenotypically distinct CD21neg naive B cell clusters in healthy
and HIV-1–infected individuals (Figs. 6 and 7). Chronic HIV-1
infection was associated with shifts of these clusters toward
phenotypes associated with an inflammatory profile such as
increased expression of CXCR3 and reduced levels of CCR7 and
CXCR5, which suggests ongoing B cell changes during disease
progression. Interestingly, prolonged ART did not revert these
phenotypic changes acquired during disease progression in the
late ART initiation group (Figs. 5 and 7 B). Of note, exhausted
T cells do not revert their phenotype upon antigen withdrawal
or immunotherapy with checkpoint inhibitors, since the ex-
haustion phenotype characterized by high expression of PD-1 is
Figure 9. CD21neg naive and CD21neg MZ B cells are in a pro-
liferative state and are prone to apoptosis. (A) Example
staining for a healthy donor. FSC-A, forward scatter area signal.
(B) Comparison of Ki-67 expression in B cell subsets in healthy
controls (n = 29) and chronic HIV-1–infected patients (n = 21).
(C) Dot plots of FITC-labeled caspase-3 inhibitor FITC-C6-
DEVD-FMK and Annexin V staining from a chronic HIV-1–infected
patient. (D) Frequencies of apoptotic CD21neg and CD21pos naive
and MZ B cells in healthy controls (n = 10) and a set of chronic
HIV-1–infected patients (n = 10), where double-positive events in
C are defined as apoptotic. Data represent single measurements
from each patient time point assessed. Comparison between
CD21neg and CD21pos naive and CD21neg and CD21pos MZ B cells
within the same individual was done using Wilcoxon signed rank
test and between healthy and HIV-1–infected individuals using
Mann–Whitney U test. *, P < 0.05; **, P < 0.01; ***, P < 0.001;
****, P < 0.0001. Numbers in dot plots in A and C indicate per-
centage of gated population.
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Figure 10. CD21neg naive and CD21neg MZ B cells are in an anergic state. (A) Histogram overlays of flow cytometric Phosflow analysis in unstimulated
(black) and BCR cross-linking stimulated (blue) CD21neg and CD21pos naive and CD21neg and CD21pos MZ B cells from a chronic HIV-1–infected patient.
(B) Tyrosine phosphorylation (log-transformed MFI values) before and upon stimulation with anti-IgG/IgA/IgM in healthy subjects (n = 10) and chronic
HIV-1–infected patients (n = 10) for CD21neg and CD21pos naive B cells, CD21neg and CD21pos MZ B cells, and IM, RM, AM, and TLM B cells. (C and D) Total
log2-transformed tyrosine phosphorylation MFI at basal levels and upon stimulation (C) and log2-transformed fold difference between unstimulated and IgG/
IgA/IgM-stimulated CD21neg naive and CD21neg MZ B cells (D) in comparison to their CD21pos counterpart from the same donors shown in B. Memory B cell
subsets are included as a control. (E) Direct comparison of the above parameters from CD21neg and CD21pos naive B cells, CD21neg and CD21pos MZ B cells, and
memory B cell subsets upon stimulation between healthy controls (n = 10) and chronic HIV-1–infected patients (n = 10). Data represent single measurements
from each patient time point assessed. Wilcoxon signed rank test was used to compare CD21neg and CD21pos naive and CD21neg and CD21pos MZ B cells within
healthy subjects and chronic HIV-1–infected patients. For the comparison between memory B cell subsets, Wilcoxon singed rank test was used. To compare
phosphorylation levels between healthy subjects and chronic HIV-1–infected patients, Mann–Whitney U test was applied. P < 0.05 was considered statistically
significant. *, P < 0.05; **, P < 0.01. Error bars depict minimum to maximum range.
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imprinted in the epigenetic landscape (Utzschneider et al., 2013;
Pauken et al., 2016). It will be interesting to explore if analogous
effects occur in the B cell compartment in HIV-1 infection. An
exception in the response pattern to ART was CD95, expression
of which decreased upon treatment (Fig. 8 B). Of note, the ac-
tivation marker CD95 is decoupled from exhaustion and de-
creases upon antigen withdrawal such as during successful ART,
while the functional and phenotypic characteristics of exhaus-
tion can persist (Sciaranghella et al., 2013).
In summary, our comprehensive longitudinal analysis of the
B cell compartment in HIV-1 infection revealed phenotypic sig-
natures associated with chronic immune activation. In particu-
lar, we document the emergence of unique CD21neg naive B cell
subsets in HIV-1 infection. Dissection of their potential func-
tional differences and developmental pathways will be impor-
tant future avenues of research to understand the role of CD21neg
naive B cells in health and disease. The emergence of anergic
naive and MZ B cells we unveil and their phenotypic definition
by down-regulation of CD21 and changed chemokine receptor
and IL-21R expression patterns will empower future studies to
define and trace these cell populations and uncover their func-
tions. The impact of CD21neg naive and CD21neg MZ B cells on the
IgA, IgM, and IgG antibody response against coinfections or
vaccines in HIV-1–infected patients will be key to resolve. This
will be particularly critical in understanding pathogenic changes
of the immune system in HIV-1 infection and will accordingly
tailor preventive and therapeutic vaccine approaches. Moni-
toring of these cell populations may be exploited as biomarkers
to predict the efficacy of vaccines and of antibody responses
against coinfections. Therapeutic interventions with the aim to
restore impaired CD21neg naive and CD21neg MZ B cells could
improve antibody responses in HIV-1 infection. The knowledge
of the phenotypic characteristics of CD21neg naive and CD21neg
MZ B cells in HIV-1 infection that our study provides will be vital
to all these endeavors.
Materials and methods
Clinical specimens and study approval
Cryopreserved peripheral blood mononuclear cells (PBMCs) and
plasma of HIV-1–infected individuals were available from sam-
ples stored in the biobank of the ZPHI. The ZPHI is an ongoing,
observational, nonrandomized, single-center cohort founded in
2002 that specifically enrolls patients with documented acute
(i.e., first 3 mo after infection) or recent (i.e., 3–6 mo after in-
fection) primary HIV-1 infection (ClinicalTrials.gov identifier
NCT00537966; Rieder et al., 2011). The ZPHI is approved by the
ethics committee of the Kantonale Ethikkommission Zürich, and
written informed consent was obtained from all participants.
The patient samples analyzed in the current study are derived
biobanked samples from two different treatment arms from a
historic study assessed as part of the ZPHI from 2002 to 2007
(Gianella et al., 2011; Wyl et al., 2011). One treatment arm (early
ART initiation group) started ART during acute infection, stayed
on ART for ≥1 yr after suppressed viremia, and then underwent
ART interruption. The second treatment arm (late ART initiation
group) delayed initiation of ART until the chronic disease stage.
Importantly, all patients enrolled in the ZPHI were recom-
mended by the treating physician to initiate early ART.
Patients who opted for early treatment could choose to stay
or to interrupt ART after being virologically suppressed ≥1 yr,
and reinitiation of ART was performed according to treatment
guidelines at that time of study (Hammer et al., 2006). The re-
maining patients opted to delay or interrupt ART at certain
stages, providing the source of the samples studied here.
Longitudinal samples of patients that started ART early
(during the acute infection stage, n = 11) and late (in the chronic
infection stage, n = 10) were analyzed and included samples from
the untreated acute and chronic stage and after 1 yr of ART (Fig. 1
A; and Tables S1 and S2). For the early ART initiation group, the
1- and 2-yr chronic infection time points were calculated from
the time point of ART cessation to guarantee comparable con-
tinuous viral replication in both groups.
Patients from both arms were included in our analysis for
whom cryopreserved PBMC samples were available at all time
points considered in our analysis (acute infection, chronic in-
fection, and prolonged ART). No other selection criteria were
applied. A separate set of 10 patients were analyzed during the
chronic infection stage for functional analysis of B cell subsets
(Figs. 9, C and D; Fig. 10; and Table S2). Patient and disease
demographics (estimated time of infection, CD4 T cell count and
plasma viral load at sampling date, age, gender, ethnicity, and
virus subtype) were available through the ZPHI database (Table
S2). PBMCs and plasma from healthy, HIV-1–uninfected donors
(n = 29) were collected in the frame of a separate clinical study
(principal investigator, H. Günthard) that was approved by the
ethics committee of the Kantonale Ethikkommission Zürich, and
written informed consent was obtained from all participants.
PBMCs were isolated by density-gradient centrifugation us-
ing LymphoPrep (Axis-Shield) fromwhole blood drawn in EDTA
vacutainer tubes (BD Biosciences). Until further processing,
PBMCs were cryopreserved using 90% inactivated FCS (Thermo
Fisher Scientific) and 10% DMSO (Sigma-Aldrich) and stored in
liquid nitrogen. Plasma was heat-inactivated for 1 h at 56°C and
stored at −80°C.
Flow cytometry
To monitor B cell populations by flow cytometry, PBMCs were
stained using an 18-parameter panel as described in detail in
Liechti et al. (2018a). Briefly, cells were thawed and washedwith
FACS buffer containing PBS (Thermo Fisher Scientific), 2% heat-
inactivated FCS (Thermo Fisher Scientific), 2 mM EDTA (Sigma-
Aldrich), and 20 µg/ml DNase (Sigma-Aldrich) and stained with
live/dead fixable near-infrared dye (Life Technologies) for
30 min, enabling dead cell exclusion. Viability staining was
followed by a surface staining step with antibodies directed
against CCR7 BV605 (G043H7; BioLegend), CD3 APC-Cy7 (SK7;
BioLegend), CD10 BV650 (HI10a; BD Biosciences), CD14 APC-Cy7
(HCD14; BioLegend), CD16 APC-Cy7 (3G8; BioLegend), CD19
BV786 (SC25C1; BD Biosciences), CD21 BV711 (B-ly4; BD Bio-
sciences), CD27 PE-CF594 (M-T271; BD Biosciences), CD38 Alexa
Fluor 700 (HIT2; BioLegend), CXCR3 PE-Cy7 (G025H7; BioL-
egend), IL-21R BV421 (2G1-K12; BioLegend), CXCR5 BV510
(RF8B2; BD Biosciences), IgA APC (polyclonal goat IgG; Jackson
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ImmunoResearch), IgG1 PE (HP6001; Southern Biotech), and
IgG3 FITC (polyclonal sheep IgG; AbD Serotec). Unlabeled
CXCR4 (12G5; BioLegend) and IgD (IA6-2; BioLegend) were
conjugated in-house with PE-Cy5.5 and PE-Cy5, respectively,
using the Lightning-Link conjugation kits from Innova Bio-
sciences according to the manufacturer’s instructions. Cells
were then fixed and permeabilized with the FoxP3/Transcrip-
tion factor staining kit (eBioscience) according to the manu-
facturer’s instructions to stain for Ki-67 PerCP-eFluor710 (clone
20Raj1; eBioscience).
Data were acquired on a BD Fortessa calibrated daily using
the BD Bioscences Cytometer Setup and Tracking module.
Staining intensity quality control was conducted as recom-
mended (Roederer et al., 2015), and individual stainings with
markers that did not fulfil requirements were excluded when
comparative analysis of intensities was performed (Fig. S1 C). To
further limit the possibility of influence from day-to-day vari-
ability in the flow cytometry analysis, all longitudinal time
points of a given patient were run on the same day. In addition,
patients assigned to the early and late ART groups were included
in all experiments to exclude batch effects. Antibodies and re-
agents used to analyze IgM, CD95, and FcRL4 expression in-
cluded CD10 BV650 (HI10a; BD Biosciences), CD19 BV510
(SJ25C1; BD Biosciences), CD21 BV711 (B-ly4; BD Biosciences),
CD7 PE-CF594 (M-T271; BD Biosciences), CD38 Alexa Fluor 700
(HIT2; BioLegend), CD95 BV421 (DX2; BioLegend), FcRL4 PE
(413D12; BioLegend), IgD APC (IA6-2; BioLegend), IgG PE-Cy7
(G18-145; BD Biosciences), IgM FITC (polyclonal goat IgG; Cal-
tag), and live/dead near-infrared dye (Life Technologies). On
some occasions, fluorescence minus one (FMO) controls con-
taining all antibodies except the one of interest were used to
determine negative and positive cells, which is particularly
useful for dim markers.
Clustering analysis
The diversity of CD21neg naive B cells was assessed using the
clustering algorithm SPADE integrated into the cytometry
analysis platform Cytobank (Chen and Kotecha, 2014). SPADE
allows clustering of cells based on similar expression pattern of
markers and visualizes clusters in minimum spanning tree
structures (Qiu et al., 2011). 17 of the 21 HIV-1–infected patients
were included in the clustering analysis. Two patients had to be
excluded because no sample from the acute time point was
available, and two were excluded due to low staining of IL-21R
and CXCR5 due to technical variation, as depicted in Fig. S1 C. As
a reference, 15 healthy controls were included in the analysis.
Clustering was done using pregated CD21neg naive B cells
including all recorded events. The target number of expected
nodes was set to 200 and down-sampling to 2%. To analyze total
longitudinal changes of CD21neg naive B cells, the flow cytometry
files of the individual time points or the control group were
concatenated and integrated into the clustering. Clustering was
based on themarkers CCR7, CXCR3, CXCR5, and IL-21R. The four
parameters chosen for clustering were characterized by bimodal
expression patterns, a requirement for best possible cluster al-
location. CD19was not selected for clustering due to its unimodal
expression profile. CXCR4 was not selected for clustering due to
variability in staining intensity (Fig. S1 C). The generated SPADE
trees showed a clear allocation of cells in clusters with specific
expression patterns (Fig. 6 A). We chose a setting of over-
clustering, by allowing for 200 different clusters, as this allows
one to build separate clusters of very rare cell populations. As a
consequence, frequent cell populations can separate into dif-
ferent clusters despite sharing phenotypic properties. There-
fore, clusters created by SPADE were further clustered using
hierarchical clustering with the Ward method Ward.D2 in R and
visualized with the heatmap.2 function. ForWard clustering and
visualization, the SPADE output (z-transformed arcsinh median
fluorescence intensities of individual clusters) of the concate-
nated chronic 2-yr samples was used due to the fact that this
measurement encompassed the highest frequency of CD21neg
naive B cells, and therefore all SPADE clusters should contain
cell events. We excluded SPADE cluster 200, which showed
unusually low CXCR5 levels below background noise. Impor-
tantly, we based the Ward clustering on the same markers used
for SPADE clustering. CXCR4 and CD19 expression of the SPADE
clusters was visualized to investigate the expression profile of
these two markers on SPADE and Ward clusters. Based on the
Ward hierarchical tree, we merged the 200 SPADE clusters into
10 Ward clusters. The arcsinh-transformed MFI values of the 10
Ward clusters were normalized between 0 and 1, with MFI
values below the 1st and above the 99th percentile set to 0 and 1,
respectively. These values were displayed as a heatmap and
colored with increments of 0.2 to depict the expression levels of
the individual Ward clusters (Fig. 7 A). Ward clusters and
markers in Fig. 7 A were clustered using complete linkage
method with Euclidean distance measure. The classification was
confirmed by manually inspecting expression profiles of Ward
clusters (Fig. 6 D). For manual analysis, the SPADE clusters of
the concatenated chronic 2-yr samples were again concatenated
according to the Ward cluster classification. The cell events of
these Ward clusters were further analyzed in FlowJo version 10
(TreeStar) to assess the unique expression profile of the Ward
clusters.
IgG ELISA
Total IgG concentrations in heat-inactivated plasma from the
HIV-1–infected patients (Table S2) were measured by ELISA as
described previously (Trkola et al., 2004). Briefly, 96-well im-
munosorbent plates (Thermo Fisher Scientific) were coatedwith
polyclonal goat anti-human IgG (2 µg/ml; Southern Biotech) in
sodium carbonate buffer, pH 8.2, for 2 h at room temperature.
PBS/2% BSA (Sigma-Aldrich) was used as a blocking reagent for
30 min at 37°C. Serial dilutions of the plasma samples were
applied to the plates and incubated for 2 h at room temperature.
Plasma IgG was detected using a biotinylated polyclonal goat
anti-human IgG (Southern Biotech; 2 ng/ml) followed by
streptavidin-alkaline phosphatase (Sigma-Aldrich; 40 ng/ml),
each diluted in PBS/2% BSA and incubated for 1 h at room
temperature. CDP-Star System (Applied Biosystems) was used
as alkaline phosphatase substrate, and luminescence was mea-
sured after 30 min with a Dynex luminometer (Magellan Bio-
sciences). Human IgG (Sigma-Aldrich) was used as a standard to
determine the concentration of plasma IgG.
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Expression of apoptosis markers
To determine the frequency of apoptotic cells, we analyzed two
major events during apoptosis using flow cytometry: cleavage of
caspase 3 and the exposure of phosphatidylserine on the outer
leaflet of the cell membrane (Segawa et al., 2014). Cryopreserved
PBMCs from 10 healthy controls and 10 chronically infected
patients were analyzed for the frequency of apoptotic cells
within the different B cell subsets (Table S2). PBMCs were
stained for 30 min with antibodies against surface markers in-
cluding CD19 biotin (HIB19; BD Biosciences), CD21 PE (B-ly4; BD
Biosciences), CD27 PE-CF594 (M-T271; BD Biosciences), IgD PE-
Cy7 (IA6-2; BioLegend), and the apoptosis markers cleaved
caspase 3 inhibitor FITC-C6-DEVD-FMK (AAT Bioquest). Sub-
sequently, live/dead near-infrared dye (Life Technologies) and
streptavidin BV421 (BioLegend) staining was performed for
30 min followed by staining with Annexin V APC (BD Bio-
sciences) according to the manufacturer’s protocol. Samples
were analyzed on either a FACS Aria III or a BD FACS Verse
immediately after staining and analyzed with FlowJo version 10.
Apoptotic cells were defined as double positive for Annexin V
and FITC-C6-DEVD-FMK (Jayaraman, 2003) after dead cell ex-
clusion using live/dead near-infrared dye.
Phosflow analysis
PBMCs were rested after thawing for 4 h in RPMI 1640 medium
(Thermo Fisher Scientific) without supplements and subse-
quently incubated in RPMI 1640 containing live/dead near-
infrared dye (Life Technologies) for 20 min at room tempera-
ture. Cells were washed, split into two wells, and resuspended in
either only RPMI 1640 for the unstimulated sample or RPMI
1640 containing 10 µg/ml goat anti-human IgG/IgA/IgM f(ab)
2 (Jackson ImmunoResearch). Stimulation was done for 5 min
including a 2-min centrifugation step to remove the medium,
followed by addition of the fixation and permeabilization solu-
tion of the Foxp3 staining kit according to the manufacturer’s
instructions (eBiosciences). Cells were fixed and permeabilized
for 45 min at 4°C and then stained with antibodies including
CD3 APC-Cy7 (SK7; BioLegend), CD10 PE-Cy5 (HI10a; BD Bio-
sciences), CD14 APC-Cy7 (HCD14; BioLegend), CD16 APC-Cy7
(3G8; BioLegend), CD19 BV510 (SJ25C1; BD Biosciences), CD21
BV711 (B-ly4; BD Biosciences), CD27 PE-CF594 (M-T271; BD Bi-
osciences), IgD APC (IA6-2; BioLegend), and total phosphor-
tyrosine PE (PY20; BD Biosciences) for 30 min at room tem-
perature. Cells were extensively washed and measured using a
BD Fortessa. Analysis was done with FlowJo 10 (TreeStar).
Assessment of the HIV-1–binding antibody response in plasma
Plasma IgG1 antibody responses were measured with a cus-
tomized multiplex immunoassay as described (Kadelka et al.,
2018; Liechti et al., 2018b). The assay enables the analysis of
IgG subclass responses against antigens derived from HIV-1.
Sources of antigens and detailed assay protocols have been de-
scribed in detail (Kadelka et al., 2018; Liechti et al., 2018b).
Antigens included matrix (p17; strain NL4-3) and capsid protein
(p24; strain BH10), linear peptides from the variable loop 3
(V3) of strains JR-FL, MN, and BG505 (V3 JR-FL, V3 MN, and
V3 BG505), monomeric gp120 (strain JR-FL; gp120 JR-FL),
monomeric gp140 (strain BG505; gp140 BG505 monomer),
native-like trimer BG505 SOSIP.664 (gp140 BG505 trimer), the
trimeric gp41 lacking the membrane-proximal external region
(SF162P3, gp41ΔMPER), linear MPER peptides encompassing the
epitopes for the bnAbs 2F5 and 4E10 (MN, MPER-2/4) and in
addition for 10E8 (MN, MPER-2/4/10). In addition, resurfaced
stabilized core 3 (RSC3) protein containing a preserved CD4
binding site (CD4bs) but lacking immunodominant variable loop
regions and its mutant RSC3 Δ371I, which does not react with
most CD4bs antibodies, were included to delineate CD4bs-
specific responses (Wu et al., 2010). To determine the anti-
CD4bs response, we subtracted the signal of RSC3 Δ371I from
RSC3 (Lynch et al., 2012). Half-maximum titers (EC50) were
calculated from dilution series of heat-inactivated plasma with
six fivefold dilutions ranging from 1:100 to 1:312,500 using a
four-parameter dose–response curve. IgG1 responses are much
stronger than IgG2 and IgG3, which is why we only focused on
IgG1 responses for Spearman correlations (Fig. S3) to get suffi-
cient signal despite the small sample sizes (acute, n = 13; chronic
2 yr, n = 14).
Statistical analysis
Statistical analyses were performed in Python 2.7 using the
package scipy.stats, in R3.5.1 using its libraries lme4, lmerTest,
multcomp, car, and Rtsne, in Prism (GraphPad), as well as with
Cytobank (for the SPADE clustering analysis in Fig. 6).
Much data in this paper is of compositional nature (Fig. 1,
B–D; Figs. 5 A, 7 B, 8, B and E; and Fig. S2, A–C). That is, the
frequencies of various B cell subsets sum up to a value ≤100%.
We used a logit transformation (logit in the R package car) to
account for this specific type of data. The logit transformation
allows more emphasis to be put on differences at both ends of
the spectrum [0%,100%] compared with log transformations
that put the emphasis solely on the lower end of the spectrum. In
Figs. 7 B and 8, B and E, some frequencies are recorded as exactly
0%. In these instances, we first performed a linear transfor-
mation of the data from [0,1] into [0.001,0.999] before the logit
transformation. For the noncompositional data analyzed in Fig. 5
B, we used a log transformation.
We used a linear mixed-effect model wherever we compared
multiple samples from the same HIV-1–infected individuals at
different disease stages (Fig. 1, B–D; Figs. 5, 7 B, 8, B and E; and
Fig. S2, A–C) to account for the correlation of repeated meas-
urements within patients. Here, the infection stage (healthy,
acute, ART, or chronic) constituted the fixed-effect term of the
model, while the patient ID constituted the random-effect term.
We also assumed that two different subjects have uncorrelated
measurements (i.e., the covariance matrix we used was zero off
the diagonal): logit(Yij) = β0 + βj Xij + ui + εij, where i = 1, …, |
healthy donors| + |HIV-infected individuals|, and j = 1 (for
healthy donors) or j = 2, 3, 4 (for HIV-infected individuals). An F
test was performed on the ANOVA table using Satterthwaite’s
method for the denominator degrees of freedom to check for
overall differences. If differences existed (P < 0.05), we further
used Tukey’s method on t test to adjust for the fact that we
consider all possible comparisons between disease stages and
healthy controls. Unlike log ratio transformation, which is
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frequently used in compositional data analysis, this approach
allowed us to test if there were differences in each individual
B cell subset between the stages (healthy, acute, ART, and
chronic), which represents the typical type of analysis in flow
cytometry. Furthermore, the approach we chose does not re-
quire the stringent assumption of equality of a multivariate
covariance matrix.
In Fig. 1 E, we applied the nonlinear dimensionality reduction
algorithm tSNE on the z-scores of the frequencies of B cell
subsets (shown in Fig. 1, B–D) to obtain a two-dimensional
representation of proximity for healthy controls (n = 29) and
different time points (acute, chronic 2 yr, and 1 yr of ART) of
HIV-1–infected individuals (n = 19 for acute time point, n = 21 for
time points chronic 2 yr and 1 yr of ART). To avoid linear de-
pendencies, we excluded the frequencies of total naive, MZ, and
memory B cells from the tSNE analysis, since subcategorizations
of these B cell subsets were already used as inputs. The dis-
tinction of clusters I and II shown as a red dotted line in Fig. 1 E
was set manually to characterize clinical features of chronically
HIV-1–infected individuals, which overlap with healthy donors.
tSNE was run with the Rtsne package in R using the following
parameter choices (perplexity, 29; theta, 0; 300,000 iterations).
The Mann–Whitney U test was used to compare the clinical
features of clusters I and II in Fig. 1 F, where clusters were de-
fined by the tSNE-mapping shown in Fig. 1 E. Linear regression
was used to describe correlations of CD21neg and CD21pos naive
and CD21neg and CD21pos MZ B cells with clinical parameters
(Fig. 2). Phenotypic comparisons between CD21neg and CD21pos
naive or CD21neg and CD21pos MZ B cell subsets within the same
patients were done using the Wilcoxon signed rank test (Figs. 3
B; 4 B; 8 C; 9, B and D; and 10, C and D) and between healthy
donors and HIV-1–infected patients using the Mann–Whitney U
test (Figs. 3 C; 4, B and C; 9, B and D; and 10 E). Spearman
correlation was used to calculate the correlation between the
indicated markers in Figs. 7 C and S3. All reported statistical
analyses are of an explorative, descriptive nature. We therefore
opted, by default, not to formally adjust for multiple testing
because false positives are less of a problem in explorative
studies than false negatives (Saville, 2018). In addition, almost
all the associations we focus on exhibit a low P value, much
lower than a Bonferroni-corrected P value. Heatmaps and hi-
erarchical clustering were generated in R3.3.1 using the heat-
map.2 function.
Online supplemental material
Fig. S1 depicts flow cytometry gating to define B cell subsets
using the 16-color flow cytometry staining panel and the signal
variation across the entire study for the markers IL-21R, CCR7,
CXCR3, CXCR4, CXCR5, Ki-67, and CD19. Fig. S2 shows the
comparison of B cell subsets between the early and late ART
group. Fig. S3 depicts the Spearman correlation analysis of the
binding antibody response against various HIV-1–derived anti-
gens and CD21neg naive and CD21neg MZ B cells and their CD21pos
counterpart from acute (n = 13) and chronically (chronic 2 yr,
n = 14) infected individuals. Table S1 contains the summarized
data of healthy controls and the individual time points of the
early and late ART group. Demographic data for each individual
and overview of the choice of samples for the individual analyses
are listed in Table S2.
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